Detalles de la búsqueda
1.
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Blood
; 143(7): 597-603, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048552
2.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Blood
; 142(18): 1518-1528, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37506339
3.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood
; 137(1): 49-60, 2021 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32693406
4.
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
Blood
; 138(17): 1583-1589, 2021 10 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34133718
5.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Haematologica
; 2023 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38031761
6.
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Blood
; 135(26): 2375-2387, 2020 06 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32299093
7.
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
Blood
; 133(25): 2664-2668, 2019 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31010846
8.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Blood
; 134(16): 1337-1345, 2019 10 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31484647
9.
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain.
Biol Blood Marrow Transplant
; 26(8): 1534-1542, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068094
10.
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Br J Haematol
; 184(5): 797-807, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30548583
11.
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Blood
; 138(19): 1901-1905, 2021 11 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34329372
12.
Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.
Blood
; 127(24): 3035-9, 2016 06 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-27069257
13.
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Blood
; 127(15): 1896-906, 2016 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26755711
14.
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Biol Blood Marrow Transplant
; 23(10): 1631-1640, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28533060
15.
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
Blood
; 126(7): 858-62, 2015 Aug 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-26089396
16.
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(8): 1127-1136, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27402145
17.
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
N Engl J Med
; 369(5): 438-47, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23902483
18.
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Blood
; 124(12): 1887-93, 2014 Sep 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25102853
19.
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Ann Hematol
; 95(12): 2033-2041, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27738789
20.
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
Haematologica
; 100(9): 1207-13, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26069291